摘要:
A compression treatment system is provided that includes a first bladder supported about a limb. A second bladder is supported about the limb. The bladders are in fluid communication with a fluid source and the bladders are inflated such that the first bladder is inflated for a first time period and the second bladder is inflated for a second time period. The second time period is initiated within the first time period. A single pressure sensor communicates with the first bladder and the second bladder.
摘要:
A compression treatment system is provided that detects the number of and type of garments connected thereto. The system includes a plurality of ports, valves connected thereto and a number of garments having one or more bladders. The bladders are in fluid communication with a fluid source in a pneumatic circuit, to provide compression therapy once a user confirms the number of and type of garments connected to the system for use by a patient. A single pressure sensor communicates with a plurality of detected bladders located in the one or more garments.
摘要:
A method and system for monitoring events related to web browser extensions includes storing a set of events for which a browser extension integrated in a web browser application registers a listener. The browser extension integrated in the web browser application is executed. Upon the occurrence of an event related to the browser extension, an invisible event page associated with the browser extension is loaded if the event is one of the set of events. Using the invisible event page, a function related to a visible object of the browser extension is executed. The invisible event page is unloaded from the browser after receiving an acknowledgement from the browser extension.
摘要:
The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.
摘要:
The present invention provides a compound of a formula (I) wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.
摘要:
The present invention provides a compound of formula (I), wherein: Z is (A) OR (B) and wherein the remaining variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of achemokine (such as CCR3) or H1 mediated disease state.
摘要:
The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
摘要:
The invention provides compounds of formula (I) wherein: T is C(O) or S(O)2; W is C(O) or S(O)2; X is CH2, O or NH; Y is CR11 or N; n is 0, 1 or 2; m is 1 or, when Y is CR11 m is 0; R1 is optionally substituted aryl or optionally substituted heterocyclyl; R2, R3, R,4, R5, R6, R7 and R8 are, independently, hydrogen or C?1-6#191 alkyl; R9 is hydrogen or C1-C6 alkyl; R10 is alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl; and R11 is hydrogen or C1-C6 allkyl; that are modulators of chemokine (especially CCR3) activity and are especially useful for treating asthma and/or rhinitis.
摘要翻译:本发明提供式(I)化合物,其中:T为C(O)或S(O)2; W是C(O)或S(O)2。 X是CH 2,O或NH; Y是CR 11或N; n为0,1或2; m为1或Y为CR 11时m为0; R 1是任选取代的芳基或任选取代的杂环基; R 2,R 3,R 3,R 5,R 5,R 6, R 7和R 8分别独立地为氢或C 1-6烷基; R 9是氢或C 1 -C 6烷基; R 9是氢或C 1 -C 6烷基; R 10是烷基,任选取代的芳基,任选取代的芳烷基或任选取代的杂环基; 并且R 11是氢或C 1 -C 6烷基; 它们是趋化因子(特别是CCR3)活性的调节剂,特别适用于治疗哮喘和/或鼻炎。
摘要:
The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
摘要:
The present invention provides a compound of formula (I), wherein: Z is (A:) OR (B) and wherein the remaining variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of achemokine (such as CCR3) or H1 mediated disease state,